The cysteine protease caspase-8 plays an essential role in apoptosis induced by death receptors. The protein synthesis inhibitor acetoxycycloheximide (Ac-CHX) has been previously shown to induce rapid apoptosis mediated by the release of cytochrome c in human leukemia Jurkat cells. In this study, the novel molecular mechanism that links caspase-8 to the mitochondrial release of pro-apoptotic proteins has been identified. Jurkat cells deficient in caspase-8 were more resistant to Ac-CHX than wild-type Jurkat cells and manifested decreased apoptosis induction and caspase activation as well as inefficient release of cytochrome c, Smac/DIABLO, and AIF into the cytosol. In contrast to Fas ligand stimulation, the general caspase inhibitor barely prevented the mitochondrial release of these pro-apoptotic proteins in Ac-CHX-treated cells, suggesting that caspase-8 activity is dispensable for triggering the mitochondrial pathway in Ac-CHX-induced apoptosis. Consistent with this notion, caspase-8-deficient Jurkat cells reconstituted with catalytically inactive caspase-8 became sensitive to Ac-CHX and exhibited apoptosis, caspase activation, the liberation of pro-apoptotic proteins into the cytosol, and Bak conformational change as efficiently as wild-type Jurkat cells. Unlike caspase-3, -6, -7, and -9, a small but significant portion of caspase-8 was found to localize in mitochondria before and after exposure to Ac-CHX. These results clearly demonstrate that caspase-8 is able to mediate the mitochondrial release of pro-apoptotic proteins in a manner independent of its proteolytic activity in Ac-CHX-induced apoptosis.
way upon engagement with corresponding ligands, death receptors recruit adaptor protein Fas-associated death domain (FADD) 2 and initiator caspase-8, forming death-inducing signaling complex (4 -7) . In death-inducing signaling complex, caspase-8 is converted into its active tetramer via dimerization and self-processing (8 -11) . The active caspase-8 tetramer is subsequently released into the cytosol and cleaves various substrates, such as effector caspases and BH3-only protein Bid, to yield their active forms (4 -7, 12) . Truncated Bid is translocated to mitochondria where it initiates activation of the caspase cascade and amplifies the intrinsic apoptosis pathway (13, 14) . Active effector caspases mediate proteolytic cleavage of many cellular proteins and ultimately dictate cellular demolition (15) .
Mitochondria play a central role in the regulation of apoptosis (16, 17) . Mitochondrial pro-apoptotic proteins, such as cytochrome c, Smac/DIABLO, and AIF, are confined to intermembrane space and are liberated into the cytosol upon multiple apoptotic stimuli (18, 19) . Cytochrome c collaborates with adaptor protein Apaf-1 to activate initiator caspase-9 in the apoptosome (20 -22) . Smac/DIABLO facilitates caspase activity by binding to and antagonizing inhibitor of apoptosis proteins (23) (24) (25) (26) (27) . AIF translocates to the nucleus where it induces caspase-independent DNA fragmentation and chromatin condensation (28, 29) .
The protein synthesis inhibitor cycloheximide (CHX) has been reported to induce apoptosis in a number of cell types (30 -32) , as well as to sensitize cells to death-receptor-mediated apoptosis by down-regulating anti-apoptotic proteins (33, 34) . Acetoxycycloheximide (Ac-CHX, initially termed as E-73) is a close structural derivative of CHX (35) (36) (37) (38) and is able to prevent de novo protein synthesis more efficiently than CHX (39 -42) . We have previously reported that Ac-CHX induces rapid processing of caspases and subsequent apoptosis with higher efficacy than CHX in human leukemia Jurkat cells (42) . More-over, Ac-CHX has been shown to induce strong activation of the c-Jun N-terminal kinase (JNK) pathway and to trigger the release of cytochrome c into the cytosol (42) . In this study, we further investigated the molecular mechanism by which Ac-CHX induces rapid apoptosis. Our results surprisingly provide evidence for the novel molecular mechanism that links caspase-8 to the mitochondrial release of pro-apoptotic proteins.
EXPERIMENTAL PROCEDURES
Cells-Human leukemia Jurkat cells, caspase-8-deficient Jurkat cell clone (I9.2) (43), FADD-deficient Jurkat cell clone (I2.1) (44) , c-FLIP L -transfected Jurkat cell clone (JFL2) (45) , and Bclx L -transfected Jurkat cell clone (Jurkat-Bcl-x L #1) (42) were maintained in RPMI 1640 medium (Invitrogen) supplemented with 10% (v/v) heat-inactivated fetal calf serum (JRH Bioscience, Lenexa, KS), 100 units/ml penicillin G (Sigma), and 100 g/ml streptomycin (Sigma).
Reagents-Ac-CHX was isolated from the culture broth of an unidentified actinomycete strain designated ML44-113F2, as previously described (41) . CHX and curcumin were purchased from Wako Pure Chemical Industries (Osaka, Japan). Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethyl ketone (z-VAD-fmk) and SP600125 were purchased from the Peptide Institute (Osaka, Japan) and Biomol Research Laboratories (Plymouth Meeting, PA), respectively.
Antibodies-Antibodies to AIF (E-1, Santa Cruz Biotechnology, Santa Cruz, CA), Bak (Ab-1, Calbiochem), Bak (NT, Millipore, Lake Placid, NY), ␤-actin (AC-15, Sigma), Bcl-2 (clone 7, BD Bioscience, Franklin Lakes, NJ), Bid (550365, BD Biosciences), caspase-3 (H-277, Santa Cruz Biotechnology), caspase-6 (3E8, Medical & Biological Laboratories (MBL), Nagoya, Japan), caspase-7 (11E4, Sigma), caspase-8 (5D3, MBL), caspase-8 (5F7, MBL), caspase-9 (5B4, MBL), cytochrome c oxidase (CoxIV) (20E8, Santa Cruz Biotechnology), cytochrome c (7H8.2C12, BD Biosciences), FADD (clone 1, BD Biosciences), Fas (B-10, Santa Cruz Biotechnology), FLAG (M2, Sigma), c-FLIP (Dave-II, Alexis, Lausen, Switzerland), JNK (#9252, Cell Signaling Technology, Inc., Beverly, MA), phospho-JNK (#9251, Cell Signaling), and Smac/DIABLO (clone 7, BD Biosciences) were commercially obtained. Rat anti-mouse caspase-8 (clone 3B10) monoclonal antibody was prepared as described previously (46) .
Assay for Apoptosis-Cells were fixed with PBS containing 4% paraformaldehyde at 4°C overnight, and then stained with 300 M Hoechst 33342 (Calbiochem). Nuclear morphology was observed under a fluorescence light microscope (Axiovert 200M, Carl Zeiss, Jena, Germany). Apoptotic cells (%) were calculated as (condensed nuclei/total nuclei) ϫ 100.
Western Blotting-Cells were washed with PBS and lysed in Triton X-100 lysis buffer consisting of 50 mM Tris-HCl (pH 7.4), 1% Triton X-100, 2 mM dithiothreitol, 2 mM sodium orthovanadate, and the protease inhibitor mixture Complete TM (Roche Diagnostics, Mannheim, Germany). Postnuclear lysates were collected as supernatants by centrifugation (15,000 ϫ g, 5 min). Protein samples (30 g/lane) were separated by SDS-PAGE and transferred onto Hybond-ECL nitrocellulose membranes (GE Healthcare, Piscataway, NJ). The transferred membranes were stained with Ponceau S and checked for equal loading of proteins before antibody reaction. The membranes were incubated with primary antibodies and then with horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA), followed by analysis using ECL Western blotting detection reagents (GE Healthcare).
Subcellular Fractionation-Cells were washed with PBS and lysed with digitonin lysis buffer (10 mM Hepes-KOH (pH 7.2), 100 M digitonin, 250 mM sucrose, 1 mM dithiothreitol, 5 mM EGTA, 2 mM MgCl 2 , 50 mM NaCl, and the protease inhibitor mixture Complete TM ) on ice for 15 min. After centrifugation (10,000 ϫ g, 5 min), cell lysates containing cytosol were recovered as supernatants. Pellets were washed once with digitonin lysis buffer and treated with Triton X-100 lysis buffer on ice for 15 min. After centrifugation (10,000 ϫ g, 5 min), cell lysates containing mitochondria were collected as supernatants (mitochondrial fraction). Cytosolic and mitochondrial fractions were analyzed by Western blotting. Alternatively, cells were washed with PBS and Dounce-homogenized with sucrose homogenization buffer (10 mM Hepes-NaOH (pH 7.4), 250 mM sucrose, 1 mM EDTA, 1 mM EGTA, Complete TM ). After repeated centrifugation (800 ϫ g, 5 min) to remove nuclei and unbroken cells, supernatants were further centrifuged (10,000 ϫ g, 10 min). Resultant precipitates were further washed twice with sucrose homogenization buffer to prepare mitochondrial fraction. Cytosolic fractions were recovered as supernatants after centrifugation (100,000 ϫ g, 60 min). Cytosolic and mitochondrial fractions were analyzed by Western blotting.
RNAi-Stealth TM RNAi duplexes targeting Bid #1(5Ј-GGG-AAGAAUAGAGGCAGAUUCUGAA-3Ј) and Bid #2 (5Ј-AAU-AGAGGCAGAUUCUGAAAGUCAA-3Ј) and negative control duplexes (Low GC duplex #2) were purchased from Invitrogen. Cells were diluted 1 day before transfection, and then suspended with GenePulser electroporation buffer (Bio-Rad). The cells were transfected with 200 nM Stealth TM RNAi duplexes using the GenePulser Xcell electroporation system (Bio-Rad) and incubated for 48 h prior to analysis.
Cell Transfection-Cells were diluted 1 day before transfection and washed three times with fetal calf serum-free RPMI 1640 medium. The cells were transfected with pEF pGK puro expression vectors (47) encoding mouse wild-type caspase-8 or mouse proteolytically inactive caspase-8 mutant (C362G) (48) or pEF pGK hygro expression vectors encoding FLAG-tagged human Bcl-2 (47) using the GenePulser Xcell electroporation system. The cells were cultured for 48 h without selection and then cultured in microtiter plates in the presence of puromycin (5 g/ml, Sigma) or hygromycin (1 mg/ml, Nacalai Tesque, Inc., Kyoto, Japan). Puromycin-and hygromycin-resistant clones expressing mouse caspase-8 and human Bcl-2 were selected by Western blotting using anti-mouse caspase-8 antibody 3B10 and anti-FLAG antibody M2, respectively.
Assay for Mitochondrial Membrane Potential-Cells were incubated with RPMI 1640 medium containing 40 nM 3,3Ј-dihexyloxacarbocyanine iodide for 15 min. The cells were washed three times with PBS containing 2% fetal calf serum and 0.02% sodium azide, and analyzed with a FACSCalibur TM flow cytometer (BD Biosciences).
Detection of Bak Conformational
Change-Bak conformational change was detected basically as described previously (49 -51) . Cells were washed with PBS and lysed with CHAPS lysis buffer (10 mM Hepes-NaOH (pH 7.4), 1% CHAPS, 150 mM NaCl, Complete TM ) on ice for 15 min. After centrifugation (10,000 ϫ g, 5 min), cell lysates were precleared with isotypespecific control antibody (Invitrogen) and then immunoprecipitated with mouse monoclonal anti-Bak antibody (Ab-1) and protein G Plus-agarose (Calbiochem). The resultant immunoprecipitates containing conformationally changed Bak were separated by SDS-PAGE and analyzed by Western blotting using rabbit polyclonal anti-Bak antibody (NT).
RESULTS

Caspase-8 Is Responsible for Apoptosis Induced by Ac-CHX-
Ac-CHX induced apoptosis in human leukemia Jurkat cells at concentrations Ͼ0.1 M (Fig. 1A) . Upon treatment with Ac-CHX, Jurkat cells started to die within 2 h and steadily underwent apoptosis thereafter (Fig. 1B) . The kinetics of Ac-CHXinduced apoptosis is very rapid and seems similar to that of Fas ligand (FasL)-induced apoptosis. Caspase-8 plays an essential role in FasL-induced apoptosis (4 -7). To determine if caspase-8 is responsible for Ac-CHX-induced apoptosis, Jurkat cells deficient in caspase-8 were compared with wild-type cells for the induction of apoptosis following exposure to Ac-CHX. Caspase-8-deficient cells were more resistant to Ac-CHX-induced apoptosis (Fig. 1A) and manifested slower induction of apoptosis upon treatment with Ac-CHX (Fig. 1B) , although they were completely resistant to FasL-induced apoptosis (Fig.  1C) . Approximately 50% of caspase-8-deficient cells underwent apoptosis when they were treated with Ac-CHX (1 M) for 5 h. These results indicate that Ac-CHX is able to induce apoptosis in a manner independent of caspase-8. Nevertheless, especially at early time points upon exposure to Ac-CHX, it seems most likely that caspase-8 is required for accelerated induction of apoptosis.
Caspase-8 Is Responsible for Caspase Activation Induced by Ac-CHX-In wild-type Jurkat cells, Ac-CHX induced processing of caspase-3 and caspase-9 into their active forms at concentrations Ͼ0.1 M ( Fig. 2A) and within 2 h (Fig. 2B) . In caspase-8-deficient cells exposed to Ac-CHX, processing of caspase-3 and caspase-9 was greatly decreased (Fig. 2, A and B) . Consistent with these results, in caspase-8-deficient cells, Ac-CHX induced little processing of caspase-6 and caspase-7 into their active forms (Fig. 2C) . Thus, these results indicate that caspase-8 is responsible for caspase activation induced by Ac-CHX.
Caspase-8 Is Responsible for Mitochondrial Release of Proapoptotic Proteins in Ac-CHX-induced Apoptosis-Mitochon-
dria play a central role in the induction of apoptosis via the release of pro-apoptotic proteins into the cytosol (16 -19) . Upon treatment with Ac-CHX, cytochrome c and Smac/DIA-BLO were released into the cytosol within 2 h, accompanied by their profound reduction in mitochondria (Fig. 3) . AIF was also released into the cytosol in Ac-CHX-treated cells, although a large part of AIF was still retained in mitochondria (Fig. 3) . In caspase-8-deficient cells, these apoptotic factors were only weakly released into the cytosol upon exposure to Ac-CHX (Fig. 3 ). These data indicate that caspase-8 is responsible for the mitochondrial release of pro-apoptotic proteins in Ac-CHXinduced apoptosis. However, because the general caspase inhibitor z-VAD-fmk prevented apoptosis induced by Ac-CHX (42) , it seems that the release of Smac/DIABLO and AIF is not essential for induction of apoptosis by Ac-CHX. However, these changes are considered to be useful markers for the mitochondrial activation during Ac-CHX-induced apoptosis.
Caspase Activity Is Dispensable for Mitochondrial Release of Pro-apoptotic Proteins in Ac-CHX-induced Apoptosis-
Caspase-8 is known to cleave Bid into its truncated form that translocates to mitochondria and induces the release of proapoptotic proteins into the cytosol in FasL-induced apoptosis (13, 14) . In contrast to FasL stimulation, z-VAD-fmk barely prevented the release of cytochrome c, Smac/DIABLO, and AIF into the cytosol in Ac-CHX-treated cells (Fig. 4A) . The possibility that z-VAD-fmk is insufficient to block caspase activity is excluded by the observations that z-VAD-fmk at the same concentration totally prevented the release of cytochrome c, Smac/ DIABLO, and AIF into the cytosol in FasL-treated cells (Fig. 4A) and that z-VAD-fmk suppressed caspase activity induced by Ac-CHX to background levels as measured using fluorescent caspase substrates (42) . Full-length Bid (p24) was cleaved into its truncated form (p15) in wild-type Jurkat cells but not caspase-8-deficient cells when treated with FasL (Fig. 4B) . However, Bid processing was still observed in caspase-8-deficient cells during Ac-CHX-induced apoptosis (Fig. 4B) . Because Ac-CHX-induced Bid processing in caspase-8-deficient cells was prevented by z-VADfmk (Fig. 4C) , it seems that Bid is cleaved not by caspase-8 but by other caspases in Ac-CHX-treated cells. To exclude the possibility that Bid is required for Ac-CHX-induced mitochondrial release of proapoptotic proteins, wild-type Jurkat cells were transiently transfected with the Stealth TM RNAi duplexes targeting Bid (Fig. 4D) . Knockdown of Bid failed to affect the release of cytochrome c, Smac/DIABLO, and AIF into the cytosol upon 2-h treatment with Ac-CHX (Fig. 4E) . Taken together, these data suggest that caspase activity is dispensable for the mitochondrial release of pro-apoptotic proteins in Ac-CHX-induced apoptosis.
Caspase-8 Is Able to Induce Apoptosis Without Its Enzymatic Activity in Ac-CHX-treated Cells-To determine if the enzymatic activity of caspase-8 is necessary for Ac-CHXinduced apoptosis, caspase-8-deficient Jurkat cells were reconstituted with wild-type caspase-8 or catalytically inactive caspase-8 mutant (C362G). Three independent transfectants expressing wild-type caspase-8 (JC8WT1, JC8WT2, and JC8WT3) and inactive caspase-8 (JC8IN1, JC8IN2, and JC8IN3) at endogenous levels comparable to those in B lymphoma A20 cells were established (Fig. 5A) . These transfectants expressed FADD and c-FLIP L at similar levels to wild-type and caspase-8-deficient cells, whereas caspase-8-deficient cells and their transfectants expressed slightly decreased levels of Fas compared with wild-type cells (Fig. 5A ).
Caspase-8 was processed into its active form containing a large subunit (p20) only when wild-type caspase-8 transfectants (JC8WT1, JC8WT2, and JC8WT3), but not inactive caspase-8 transfectants (JC8IN1, JC8IN2, and JC8IN3), were exposed to FasL (Fig. 5B) . Consistent with these results, FasL was able to induce apoptosis in wild-type caspase-8 transfectants (JC8WT1, JC8WT2, and JC8WT3) but not inactive caspase-8 transfectants (JC8IN1, JC8IN2, and JC8IN3) (Fig. 5D) . Therefore, these data clearly indicate that the enzymatic activity of caspase-8 is essential for FasL-induced apoptosis. By contrast, caspase-8 was processed into the p43 intermediate form but not the p20 large subunit when both wild-type caspase-8 transfectants (JC8WT1, JC8WT2, and JC8WT3) and inactive caspase-8 transfectants (JC8IN1, JC8IN2, and JC8IN3) were treated with Ac-CHX (Fig. 5C) . Therefore, it seems that caspase-8 is cleaved not by self-processing but by other downstream caspases in Ac-CHX-treated cells. This notion was further supported by the observation that caspase-8 processing did not occur in Bcl-x L -overexpressing cells during Ac-CHX-induced apoptosis, whereas FasL stimulation induced processing of caspase-8 into the active form containing the large subunit (supplemental Fig. S1 and Ref. 42 ). As shown in Figs. 1 and 5E , compared with wild-type cells, Ac-CHX did not efficiently induce apoptosis in caspase-8-deficient cells. In contrast to FasL stimulation, Ac-CHX was able to induce apoptosis at similar levels in both wildtype caspase-8 transfectants (JC8WT1, JC8WT2, and JC8WT3) and inactive caspase-8 transfectants (JC8IN1, JC8IN2, and JC8IN3) (Fig. 5E) .
It has been shown that CHX suppresses the anti-apoptotic activity of c-FLIP by down-regulation (52) (53) (54) . To exclude the possibility that Ac-CHX similarly down-regulates c-FLIP expression, thereby resulting in caspase activation and subsequent apoptosis, c-FLIP levels as well as induction of apoptosis were compared in Jurkat cells upon treatment with Ac-CHX or CHX. Although both Ac-CHX and CHX reduced c-FLIP expression to barely detectable levels in wild-type Jurkat cells (Fig. 5F ), only Ac-CHX, but not CHX, potently induced apoptosis (Fig. 5H) . Moreover, under conditions where c-FLIP expression was overexpressed beyond the physiological levels, Ac-CHX was still able to induce apoptosis as comparable as wild-type cells (Fig. 5, F and H) . Therefore, it seems unlikely that c-FLIP down-regulation is required for Ac-CHX-induced apoptosis. In caspase-8-deficient Jurkat cells reconstituted with wild-type caspase-8 or inactive caspase-8, c-FLIP expression was also down-regulated to background levels upon treatment with Ac-CHX or CHX (Fig. 5G) . Again, Ac-CHX, but not CHX, potently induced apoptosis in these caspase-8 transfectants (Fig. 5I) . These results suggest that CHX-induced c-FLIP downregulation is not sufficient to induce apoptosis and that one or more positive apoptotic signals are triggered by caspase-8 irrespective of its catalytic activity upon treatment with Ac-CHX. Therefore, it seems likely that not only wild-type caspase-8 but also catalytically inactive caspase-8 work as an activator for Ac-CHX-induced apoptosis.
We have previously shown that Ac-CHX induces apoptosis in a JNK-dependent manner in wild-type Jurkat cells (42) . Consistent with this finding, in caspase-8-deficient cells reconstituted with wild-type caspase-8 or catalytically inactive caspase-8, Ac-CHX-induced apoptosis was markedly decreased by small molecular inhibitors of the JNK pathway (i.e. curcumin and SP600125 in Refs. 55 and 56) (supplemental Fig. S2) .
Caspase-8 Induces Mitochondria-dependent Apoptosis Signaling Pathway Without Its Enzymatic Activity in Ac-CHX-
treated Cells-Ac-CHX induced processing of caspase-3 and caspase-9 in the wild-type caspase-8 transfectant JC8WT1 and the inactive caspase-8 transfectant JC8IN1 in a manner comparable to wild-type cells (Fig. 6A) . The release of cytochrome c, Smac/DIABLO, and AIF induced by Ac-CHX was also substantially recovered in the inactive caspase-8 transfectant JC8IN1 (Fig. 6B) . As an additional apoptotic change in mitochondria, compared with wild-type cells, Ac-CHX did not efficiently reduce mitochondria membrane potential in caspase-8-deficient cells, whereas Ac-CHX-induced reduction of mitochondria membrane potential was recovered in the wild-type caspase-8 transfectant JC8WT1 and the inactive caspase-8 transfectant JC8IN1 (Fig. 6C) . Moreover, overexpression of Bcl-2 blocked the mitochondrial release of cytochrome c, Smac/DIABLO, and AIF induced by Ac-CHX in wild-type cells (Fig. 6, D and E) , as well as caspase-8-deficient cells reconstituted with wild-type caspase-8 (Fig. 6, F and G) or inactive caspase-8 (Fig. 6, H and I) . These results suggest that the mitochondrial activation is essential for Ac-CHX-induced apoptosis even under conditions where catalytically inactive caspase-8 is operational.
The JNK inhibitor SP600125 prevented the mitochondrial release of cytochrome c, Smac/DIABLO, and AIF in wild-type Jurkat cells as well as caspase-8-deficient Jurkat cells reconstituted with wild-type and catalytically inactive caspase-8 (supplemental Fig. S3 ). Moreover, JNK was phosphorylated upon treatment with Ac-CHX in caspase-8-deficient cells and their caspase-8 transfectants as efficiently as wild-type cells (supplemental Fig. S4A ). FADD-deficient Jurkat cells also manifested Ac-CHX-induced JNK phosphorylation as comparable as wildtype cells (supplemental Fig. S4B ). Therefore, these results suggest that caspase-8 and its catalytic activity are not required for JNK activation but essential for the mitochondrial activation following JNK activation during Ac-CHX-induced apoptosis.
Bak Conformational Change Is Induced by Ac-CHX and Inhibited by Bcl-x L and the JNK Inhibitor-The Bcl-2 family members such as Bax and Bak undergo conformational changes prerequisite to mitochondrial outer membrane permeabilization, which allows the mitochondrial release of pro-apoptotic proteins (16 -19) . Therefore, Bak conformational change was assessed by immunoprecipitation using anti-Bak antibody (Ab-1) reactive to the NH 2 terminus of Bak (49 -51) . Upon treatment with Ac-CHX, Bak conformational change was induced within 2 h in wild-type Jurkat cells (Fig. 7A) , while Ac-CHX-induced Bak conformational change was suppressed in Jurkat cells overexpressing Bcl-x L (Fig. 7B) . Moreover, caspase-8-deficient cells reconstituted with wild-type caspase-8 and catalytically inactive caspase-8 manifested Ac-CHX-induced Bak conformational change as comparable as wild-type cells (Fig. 7C) . SP600125 prevented Bak conformational change induced by Ac-CHX in wild-type cells and these caspase-8 transfectants (Fig. 7C) . These data suggest that JNK is involved in Bak activation during Ac-CHX-induced apoptosis.
A Small Portion of Caspase-8 Is Localized in Mitochondria before and after Exposure to Ac-CHX-To address the question how caspase-8 promotes the release of pro-apoptotic proteins from mitochondria without its catalytic activity, subcellular localization of caspase-8 was investigated (Fig. 8) . Wild-type Jurkat cells were treated with Ac-CHX for different time points, and cytosolic and mitochondrial fractions were prepared by the conventional method using Dounce homogenization and sequential centrifugation. Caspase-3, -6, -7, and -9 were barely detectable in the mitochondrial fraction, whereas the mitochondrial marker CoxIV and Bcl-2 were undetectable in the cytosolic fraction, indicating that the contamination of the cytosolic fraction into the mitochondrial fraction is negligible. Intriguingly, although caspase-8 is mostly recovered from the cytosolic fraction, a small but significant portion of caspase-8 was present in the mitochondria fraction before and after exposure to Ac-CHX. The p43 fragment of caspase-8 was also detected in the mitochondrial fraction during Ac-CHX-induced apoptosis. Unlike caspase-8, FADD was undetectable in the mitochondria fraction in untreated cells and Ac-CHXtreated cells.
DISCUSSION
It is well established that caspase-8 plays an essential role in deathreceptor-induced apoptosis and that the capability of caspase-8 to induce apoptosis solely depends on its catalytic activity (4 -7). We have previously reported that the protein synthesis inhibitor Ac-CHX induces JNK-dependent apoptosis via the release of cytochrome c in human leukemia Jurkat cells (42) . In this study, we have further shown that Jurkat cells deficient in caspase-8 are more resistant to Ac-CHX than wild-type Jurkat cells and manifest decreased liberation of mitochondrial pro-apoptotic proteins in Ac-CHX-induced apoptosis. Surprisingly, caspase-8-deficient Jurkat cells reconstituted with catalytically inactive caspase-8 became sensitive to Ac-CHX and underwent apoptosis via the mitochondrial pathway in a manner comparable to wild-type Jurkat cells. Moreover, a small portion of caspase-8 was present in mitochondria before and after treatment with Ac-CHX. Taken together, these results clearly demonstrate that caspase-8 can induce apoptosis in a manner independent of its catalytic activity in Ac-CHX-treated cells.
In response to FasL stimulation, caspase-8 mediates the proteolytic cleavage of Bid into truncated Bid, which is translocated to mitochondria where it triggers the release of pro-apoptotic proteins (13, 14) . Although FasL-induced Bid processing was barely detectable in caspase-8-deficient Jurkat cells, Ac-CHX-induced Bid processing still occurred in caspase-8-deficient Jurkat cells and was blocked by the caspase inhibitor. These results suggest that Bid is processed by effector caspases other than caspase-8 in Ac-CHX-induced apoptosis. This interpretation is consistent with previous reports showing that Bid cleavage is catalyzed by caspase-3 or possibly other downstream caspases in Jurkat cells exposed to apoptosis-inducing stimuli, such as anticancer drugs (57, 58) . In addition, we have observed that mitochondrial pro-apoptotic proteins are released in Ac-CHX-treated cells under conditions where caspase activity was suppressed by z-VAD-fmk to background levels (this study and Ref. 42) . Bid knockdown did not affect the mitochondrial release of pro-apoptotic proteins in Ac-CHX-treated cells. Therefore, it is most likely that Bid processing is dispensable for the initial triggering of the mitochondrial apoptosis pathway in Ac-CHX-induced apoptosis but may be used at later time points as the amplification loop as previously reported (57, 58) .
We have shown here that caspase-8 mediates mitochondrial apoptotic changes without its proteolytic activity in Ac-CHXtreated cells. Upon engagement with death receptors, caspase-8 is processed into the active tetramer containing the p18 large subunit, which is released into the cytosol and cleaves downstream substrates (such as caspase-3) essential for apoptosis execution (4 -7) . Under conditions where c-FLIP is sufficiently expressed, caspase-8 heterodimerizes with c-FLIP to mainly form the heterodimer consisting of caspase-8(p43) and c-FLIP(p43), which is membrane-bound and catalytically active (59 -61) . The caspase-8/c-FLIP heterodimer is unable to induce apoptosis under physiological conditions but able to induce NF-B activation (48, 62) . In Ac-CHX-treated cells, caspase-8 was cleaved into the p43 fragment but not the p18 large subunit. Moreover, in contrast to FasL stimulation, Ac-CHX-induced caspase-8 processing was inhibited completely by Bcl-x L overexpression but not by c-FLIP overexpression (42) . Therefore, caspase-8 processing into the p43 fragment during Ac-CHX-induced apoptosis seems to be mediated not by self-processing, but by effector caspases downstream of the mitochondrial pathway.
Cytochrome c and Smac/DIABLO were induced to be released into the cytosol within 2 h upon exposure to Ac-CHX, whereas AIF was released more slowly and incompletely from mitochondria. The difference in mitochondrial release of these pro-apoptotic proteins is in agreement with a recent study that used fluorescence labeling of proteins and chemical compounds (staurosporine and actinomycin D) as apoptosis inducers (63) . Among these mitochondrial pro-apoptotic proteins, it seems that cytochrome c plays an important role in Ac-CHXinduced caspase activation and subsequent apoptosis, largely because z-VAD-fmk prevented Ac-CHX-induced caspase activation and subsequent apoptosis (42) .
Ribotoxic stress response caused by protein synthesis inhibitors triggers the activation of the MAPK superfamily, thereby leading to diverse cellular responses, including apoptosis (42, 64 -68) . Indeed, Ac-CHX was able to induce rapid and sustained activation of ERK, JNK, and p38 MAPK (42, 68) . In Jurkat cells, structurally different inhibitors targeting the JNK pathway selectively prevented Ac-CHX-induced cytochrome c release and subsequent apoptosis (42) , suggesting that the JNK pathway plays a role in Ac-CHX-induced apoptosis. It has been reported that activation of the JNK pathway by DNA-damaging agents or dominant-active MEKK1 induces FasL up-regulation and subsequent apoptosis in Jurkat cells (69, 70) . It has been also reported that the JNK activation by dominant-active MKK7 leads to FADD-dependent but FasL-independent apoptosis in Jurkat cells (71) . However, it seems unlikely that conventional caspase-8 activation via the Fas-FasL interaction participates in Ac-CHX-induced apoptosis, largely due to the observations that c-FLIP overexpression failed to block Ac-CHXinduced apoptosis and that the caspase-8 p18 large subunit was barely detectable during Ac-CHX-induced apoptosis.
JNK activation is known to be required by the mitochondrial apoptotic pathway in response to various physical and chemical stimuli (72) . Among the Bcl-2 family of proteins, it has been shown that the Bax subfamily (Bax and Bak) and the BH3-only subfamily (Bim, Bmf, and Bid) induce apoptosis in a JNK-dependent fashion (73) (74) (75) . However, except for Bid processing (13, 14) , the mechanistic link between caspase-8 and above Bcl-2 family members has yet to be known. In this study, Ac-CHX was able to induce Bak conformational change in Jurkat cells, and this was found to be dependent on JNK activation. Thus, these results imply that caspase-8 may induce the mitochondrial activation via the Bak conformational change during Ac-CHX-induced apoptosis.
We provide evidence that, unlike caspase-3, -6, -7, and -9, a small portion of caspase-8 is localized in mitochondria before and after exposure to Ac-CHX. These findings are in line with the previous reports showing that caspase-8 is localized to mitochondria in several cell lines, including Jurkat cells (76 -78) . More recently, it has been shown that a mitochondriaspecific phospholipid cardiolipin anchors caspase-8 at contact sites between inner and outer mitochondrial membranes in type II cells (79) . Because Jurkat cells are classified to type II cells (80) , cardiolipin may recruit caspase-8 to mitochondria in Jurkat cells. However, in contrast to the finding that caspase-8 undergoes oligomerization and self-processing into active forms able to cleave Bid on mitochondria upon Fas stimulation (79) , our results have shown that caspase-8 signals mitochondrial release of pro-apoptotic proteins independently of Bid during Ac-CHX-induced apoptosis. The apparent inconsistency for the requirement for caspase-8 catalytic activity may be largely due to different apoptosis stimuli and/or different cell types between two studies. Therefore, at least in Jurkat cells, it has been proposed that caspase-8 may directly or indirectly interact with mitochondrial component(s), including cardiolipin, and stimulate to induce the mitochondrial release of proapoptotic proteins via the protein-protein interaction without its catalytic activity during Ac-CHX-induced apoptosis. Identification of mitochondrial protein(s) interacting with caspase-8 is necessary to understand the molecular basis how catalytically inactive caspase-8 promotes the release of pro-apoptotic proteins from mitochondria.
It has been reported that CHX at concentrations of 5-20 g/ml (15-60 M) induced apoptosis via a FADD-dependent mechanism in Jurkat cells (32) . During the CHX-induced apoptosis, none of the caspase inhibitors, including z-VAD-fmk, prevented the release of cytochrome c from mitochondria (32) . These findings are consistent with our present results that Ac-CHX-induced release of pro-apoptotic proteins from mitochondria is insensitive to z-VAD-fmk, although Ac-CHX induced rapid apoptosis with much higher efficacy than CHX (42) . Ac-CHX has greater protein synthesis inhibitory activity and is able to stimulate JNK activation at much lower concentrations than CHX (41, 42, 68) . In this regard, Ac-CHX may be a better tool to induce apoptosis than CHX. Further investigation will help us gain an insight into the novel mechanistic link between caspase-8 and the mitochondrial release of pro-apoptotic proteins during Ac-CHX-induced apoptosis.
